USPTO Examiner SKELDING ZACHARY S - Art Unit 1644

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18638307COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERSApril 2024June 2024Allow200YesNo
18492221T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONSOctober 2023September 2024Allow1120YesNo
18492310T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONSOctober 2023December 2024Abandon1320YesNo
18358833METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONSJuly 2023January 2024Allow610YesNo
18339197IMMUNOMODULATORY FUSION PROTEINS AND USES THEREOFJune 2023March 2025Allow2121NoNo
18170941BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOFFebruary 2023October 2023Allow810YesNo
18170969BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOFFebruary 2023November 2023Allow911YesNo
18169464Antigen Binding Molecules Targeting SARS-CoV-2February 2023December 2023Allow1011NoNo
18069749COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINSDecember 2022December 2023Allow1211YesNo
18058162SYNOVIAL EXTRACELLULAR MATRIX-SPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING REGULATORY T CELLS TO TREAT AUTOIMMUNE DISEASESNovember 2022June 2023Allow701NoNo
18048621METHODS FOR INCREASING T-CELL FUNCTIONOctober 2022September 2023Allow1001YesNo
17930018ANTI-CD3 ANTIBODIES AND METHODS OF USESeptember 2022June 2025Allow3300NoNo
17854227LAG3 Binding PeptidesJune 2022August 2024Allow2621YesNo
17844982T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONSJune 2022July 2023Allow1321NoNo
17718152METHODS FOR SELECTIVE EXPANSION OF GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOFApril 2022March 2025Allow3500YesNo
17762902THERAPEUTIC NEUTRALIZATION ANTIBODIES FOR THE TREATMENT OF PEANUT ALLERGYMarch 2022June 2025Allow3800YesNo
17701283COMPOSITIONS COMPRISING REGULATORY T CELLS AND METHODS OF USING THE SAMEMarch 2022June 2025Abandon3821YesNo
17700160HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLSMarch 2022August 2022Allow510NoNo
17691559METHODS OF USING IL-21 FOR ADOPTIVE IMMUNOTHERAPY AND IDENTIFICATION OF TUMOR ANTIGENSMarch 2022December 2024Abandon3301NoNo
17691565COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPYMarch 2022October 2024Allow3201NoNo
17691569T CELL RECEPTORS RECOGNIZING HLA-A1-RESTRICTED MAGE-A3March 2022June 2025Allow3921YesNo
17638923IMMUNE SYNAPSE-STABILIZING CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLFebruary 2022January 2024Allow2311YesNo
17680021ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPESFebruary 2022December 2024Abandon3401YesNo
17575577NOVEL MODULATORSJanuary 2022March 2025Allow3811YesNo
17561065METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONSDecember 2021September 2024Allow3311NoNo
17559382MONOCLONAL ANTIBODY AND A METHOD OF USE FOR THE TREATMENT OF LUPUSDecember 2021February 2025Allow3800NoNo
17559935BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIADecember 2021August 2023Allow2031YesYes
17544539COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENSDecember 2021August 2022Allow911YesNo
17535318ANTI-MUTATED KRAS T CELL RECEPTORSNovember 2021January 2025Allow3811YesNo
17528836T CELL WHICH EXPRESSES A GAMMA-DELTA T CELL RECEPTOR (TCR) AND A CHIMERIC ANTIGEN RECEPTOR (CAR)November 2021February 2025Allow3911NoNo
17610325REGULATORY T CELLS TARGETED BY LYMPHOTOXIN ALPHA BLOCKING AGENT AND USES THEREOFNovember 2021July 2024Allow3201YesNo
17516350BISPECIFIC BINDING MOLECULESNovember 2021December 2024Allow3700NoNo
17513621IMMUNOGLOBULINS BINDING HUMAN VGAMMA9VDELTA2 T CELL RECEPTORSOctober 2021March 2022Allow401YesNo
17512195COMPOSITIONS AND METHODS FOR MODULATING DELTA GAMMA CHAIN MEDIATED IMMUNITYOctober 2021April 2024Allow3021YesNo
17511218ANTI-ALPHABETATCR ANTIBODYOctober 2021June 2025Allow4312YesNo
17505515CELLS COMPRISING NON-HLA RESTRICTED T CELL RECEPTORSOctober 2021June 2023Abandon1941YesYes
17496580COMPOSITIONS AND METHODS FOR USE OF RECOMBINANT T CELL RECEPTORS FOR DIRECT RECOGNITION OF TUMOR ANTIGENOctober 2021March 2025Allow4210NoNo
17494610FUSION PROTEIN FOR USE IN THE TREATMENT OF HVG DISEASEOctober 2021November 2024Abandon3712NoNo
17493685ENGINEERED GAMMA DELTA T-CELLSOctober 2021March 2025Allow4111NoNo
17493386HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLSOctober 2021February 2022Allow410YesNo
17475686TCR-ENRICHED CLONOTYPE, ACQUISITION METHOD AND USE THEREOFSeptember 2021January 2025Allow4011YesNo
17470386Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationSeptember 2021June 2025Abandon4511NoNo
17397656NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAMEAugust 2021February 2025Abandon4211YesNo
17397841IDENTIFICATION AND USE OF T CELL EPITOPES IN DESIGNING DIAGNOSTIC AND THERAPEUTIC APPROACHES FOR COVID-19August 2021December 2022Abandon1621YesNo
17393682CD3-Binding Molecules Capable of Binding to Human and Non-Human CD3August 2021March 2024Allow3110NoNo
17372070Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationJuly 2021June 2024Abandon3510NoNo
17361524T CELL RECEPTORSJune 2021November 2024Abandon4111NoNo
17304924BCMA T CELL-ANTIGEN COUPLERS AND USES THEREOFJune 2021May 2022Allow1111YesNo
17353409HUMAN ALPHA FETOPROTEIN-SPECIFIC T CELL RECEPTORS AND USES THEREOFJune 2021August 2024Allow3801YesNo
17345425REDIRECTED CELLS WITH MHC CHIMERIC RECEPTORS AND METHODS OF USE IN IMMUNOTHERAPYJune 2021November 2024Abandon4111NoNo
17338972COMPOSITIONS AND METHODS FOR IMMUNOTHERAPYJune 2021January 2025Abandon4341YesNo
17327232BCMA-CAR-NATURAL KILLER (NK) CELLS AND METHODS RELATED THERETOMay 2021August 2021Allow300YesNo
17313761METHOD OF DETECTING NEW IMMUNOGENIC T CELL EPITOPES AND ISOLATING NEW ANTIGEN-SPECIFIC T CELL RECEPTORS BY MEANS OF AN MHC CELL LIBRARYMay 2021September 2024Allow4111YesNo
17307351USE OF A CD6 BINDING PARTNER AND METHOD BASED THEREONMay 2021April 2025Abandon4720NoYes
17243932PEPTIDES FROM NPSR1April 2021February 2024Abandon3401NoNo
17290188BINDING DOMAINApril 2021December 2024Allow4410NoNo
17287307T-CELL RECEPTOR CONSTANT REGION 1 ANTIBODY OR T-CELL RECEPTOR CONSTANT REGION 2 ANTIBODYApril 2021February 2024Allow3400YesNo
17234726METHODS OF TREATING POLYCYSTIC KIDNEY DISEASEApril 2021June 2024Allow3811NoNo
17226987Methods for Treating and/or Preventing Graft-Versus-Host Disease and/or Diffuse Alveolar Hemorrhage and/or Veno-Occlusive Disease Associated with Hematopoietic Stem Cell TransplantApril 2021October 2023Allow3010NoNo
17217837METHODS FOR INHIBITING FIBROSIS IN A SUBJECT IN NEED THEREOFMarch 2021October 2024Abandon4220NoNo
17278504HIGH AFFINITY CELL RECEPTOR FOR RECOGNIZING AFP ANTIGENMarch 2021December 2024Allow4511YesNo
17203396Antibodies to MASP-2March 2021July 2022Abandon1622NoNo
17275808SINGLE CHAIN CONSTRUCTSMarch 2021January 2025Abandon4611NoNo
17192399FUSION PROTEIN AND ITS APPLICATON IN PREPARING MEDICINE FOR TREATING TUMOR AND/OR VIRAL INFECTIONMarch 2021July 2024Allow4101YesNo
17191694ANTI-IDIOTYPE ANTIBODIES AND METHODS OF USING THE SAMEMarch 2021January 2024Abandon3411NoNo
17181778Medical Device for Administering Anti-IL-23 AntibodiesFebruary 2021November 2023Allow3310NoNo
17181983Antibodies to MASP-2February 2021September 2021Allow601NoNo
17175501BISPECIFIC BINDING MOLECULESFebruary 2021April 2021Allow200NoNo
17175565UNIVERSAL PLATFORM FOR CAR THERAPY TARGETING A NOVEL ANTIGENIC SIGNATURE OF CANCERFebruary 2021February 2024Abandon3641NoYes
17175571UNIVERSAL PLATFORM FOR CAR THERAPY TARGETING A NOVEL ANTIGENIC SIGNATURE OF CANCERFebruary 2021February 2024Abandon3641NoYes
17172925ENGINEERED INVARIANT NATURAL KILLER T (INKT) CELLS AND METHODS OF MAKING AND USING THEREOFFebruary 2021August 2024Allow4211NoNo
17171804PURIFIED ANTIBODY COMPOSITIONFebruary 2021December 2021Abandon1010NoNo
17166497KIT CONTAINING MEDIUM FOR CULTURING NATURAL KILLER CELLS AND METHOD OF EFFECTIVELY CULTURING NATURAL KILLER CELLS USING THE SAMEFebruary 2021November 2022Allow2201YesNo
17148487HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLSJanuary 2021March 2021Allow200YesNo
17146814ANTI-B7-H6 ANTIBODY, FUSION PROTEINS, AND METHODS OF USING THE SAMEJanuary 2021April 2024Allow3911YesNo
17259090ANTIBODIES COMPRISING A POLYPEPTIDE INSERTED IN FRAMEWORK 3 REGIONJanuary 2021January 2024Allow3700YesNo
17257671SOLUBLE MULTIMERIC IMMUNOGLOBULIN-SCAFFOLD BASED FUSION PROTEINS AND USES THEREOFJanuary 2021June 2024Abandon4101NoNo
17138387METHOD FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASESDecember 2020September 2024Abandon4420NoNo
17254105COMPOSITIONS INCLUDING CD3 ANTIGEN BINDING FRAGMENTS AND USES THEREOFDecember 2020June 2024Allow4221YesNo
17125922TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERSDecember 2020November 2023Allow3510NoNo
17125135NOVEL ENGINEERED T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAMEDecember 2020November 2023Allow3510NoNo
17124991MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERSDecember 2020April 2024Abandon4001NoNo
17125275MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFalpha-RELATED DISORDERSDecember 2020June 2024Abandon4201NoNo
17121513METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISORDERS IN PATIENTS WITH ELEVATED LEVELS OF CXCL9 AND OTHER BIOMARKERSDecember 2020December 2024Allow4812YesNo
17114835TREATMENT WITH ANTI-KIR3DL2 AGENTSDecember 2020December 2023Allow3710NoNo
17100223COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPYNovember 2020February 2022Allow1521YesNo
17098226CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USENovember 2020November 2023Allow3610NoNo
17089578IMMUNE CELLS ENGINEERED TO EXPRESS CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IN IMMUNOTHERAPYNovember 2020June 2021Allow701YesNo
17050289CHIMERIC HLA ACCESSORY RECEPTOROctober 2020August 2024Abandon4611YesNo
17047232CHIMERIC ANTIGEN RECEPTOR SPECIFIC FOR INTERLEUKIN-23 RECEPTOROctober 2020January 2024Allow3900YesNo
17034454COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERSSeptember 2020June 2024Allow4520YesNo
17040387Neutralization of Human Cytokines with Membrane-Bound Anti-Cytokine Non-Signaling Binders Expressed in Immune CellsSeptember 2020June 2025Allow5731YesNo
17010798HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLSSeptember 2020January 2021Allow401YesNo
17008316COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCERAugust 2020March 2024Allow4310YesNo
17000143NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAMEAugust 2020November 2023Allow3910NoNo
16989602COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINSAugust 2020December 2020Allow400YesNo
16989606COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINSAugust 2020December 2020Allow400YesNo
16984287Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the SameAugust 2020December 2024Abandon5221NoNo
16984509Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationAugust 2020January 2024Allow4110NoNo
16944816ANTI-CD3 ANTIBODIES AND METHODS OF USE THEREOFJuly 2020April 2024Abandon4520NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SKELDING, ZACHARY S.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
8
Examiner Affirmed
4
(50.0%)
Examiner Reversed
4
(50.0%)
Reversal Percentile
69.3%
Higher than average

What This Means

With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
119
Allowed After Appeal Filing
14
(11.8%)
Not Allowed After Appeal Filing
105
(88.2%)
Filing Benefit Percentile
12.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 11.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SKELDING, ZACHARY S - Prosecution Strategy Guide

Executive Summary

Examiner SKELDING, ZACHARY S works in Art Unit 1644 and has examined 1,038 patent applications in our dataset. With an allowance rate of 57.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner SKELDING, ZACHARY S's allowance rate of 57.4% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SKELDING, ZACHARY S receive 1.71 office actions before reaching final disposition. This places the examiner in the 49% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SKELDING, ZACHARY S is 38 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +51.5% benefit to allowance rate for applications examined by SKELDING, ZACHARY S. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 24.7% of applications are subsequently allowed. This success rate is in the 27% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 37.4% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 86.4% of appeals filed. This is in the 77% percentile among all examiners. Of these withdrawals, 82.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 44.9% are granted (fully or in part). This grant rate is in the 50% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 5.6% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.3% of allowed cases (in the 60% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.